Design and Development of Bioceramic Based Functionalized PLGA Nanoparticles of Risedronate for Bone Targeting: In-vitro Characterization and Pharmacodynamic Evaluation

Overview

Journal Pharm Res

Specialties Pharmacology
Pharmacy

Date 2015 Apr 5

PMID 25840949

Citations 6

Authors

Purnima Rawat

Kapil Manglani

Sarika Gupta

Abul Kalam

Divya Vohora

Farhan Jalees Ahmad

Sushama Talegaonkar

Affiliations

Soon will be listed here.

Abstract

Purpose: Bioceramic(Hydroxyapatite) based Poly(D,L-lactide-co-glycolide) (PLGA) and polyethylene glycol (PEG) nanoparticles of Risedronate was prepared by dialysis method for bone-targeting.

Methods: Risedronate, a targeting moiety that has a strong affinity for bone, was conjugated to PLGA via carbodiimide chemistry. Mono-methoxy PEG(mPEG)-PLGA block polymers were synthesized and used to impart surface hydrophilicity to nanoparticles to avoid its uptake by reticuloendothelial system (RES). The structure of prepared di block copolymers were characterized by FT-IR and NMR spectrometry. Risedronate was adsorbed on the surface of hydroxyapatite (RIS-HA) and it was conjugated with different ratios of mPEG-PLGA. The formation of surface-modified PLGA nanoparticle prepared with various ratios of risedronate as well as hydroxyapatite and mPEG was confirmed by (1)H NMR and FT-IR spectrometry.

Results: Size and % entrapment of the prepared nanoparticle was found to be 79.3 ± 2.3 nm and 93 ± 3.1%. Transmission electron microscopy (TEM) revealed that mPEG-PLGA-RIS-HA nanoparticles possess smooth and uniform surface. Pharmacodynamic study was performed on Dexamethasone (DEX) induced osteoporotic model. The effect of various formulations (mPEG-PLGA-RIS, mPEG-PLGA-RIS-HA and RISOFOS tablet) on bone was studied by Volume bone density (VBD) and by histopathological evaluation. Interestingly mPEG-PLGA-RIS-HA, showed a significant enhancement in bone micro-architecture when compared with other formulations.

Conclusions: The results strongly implicated that mPEG-PLGA-RIS-HA has a therapeutic benefits over risedronate sodium monotherapy for the treatment of osteoporosis in a rat model.

Citing Articles

BBD Driven Fabrication of Hydroxyapatite Engineered Risedronate Loaded Thiolated Chitosan Nanoparticles and Their In Silico, In Vitro, and Ex Vivo Studies.

Saifi Z, Ralli T, Rizwanullah M, Alam M, Vohora D, Mir S Micromachines (Basel). 2023; 14(12).

PMID: 38138351 PMC: 10745864. DOI: 10.3390/mi14122182.

Enhancing Osteoporosis Treatment through Targeted Nanoparticle Delivery of Risedronate: In Vivo Evaluation and Bioavailability Enhancement.

Saifi Z, Shafi S, Ralli T, Jain S, Vohora D, Mir S Pharmaceutics. 2023; 15(9).

PMID: 37765307 PMC: 10534762. DOI: 10.3390/pharmaceutics15092339.

Molecular Dynamics Studies of Poly(Lactic Acid) Nanoparticles and Their Interactions with Vitamin E and TLR Agonists PamCSK and PamCSK.

Megy S, Aguero S, da Costa D, Lamrayah M, Berthet M, Primard C Nanomaterials (Basel). 2020; 10(11).

PMID: 33167538 PMC: 7694526. DOI: 10.3390/nano10112209.

Nanostructured Biomaterials for Bone Regeneration.

Lyons J, Plantz M, Hsu W, Hsu E, Minardi S Front Bioeng Biotechnol. 2020; 8:922.

PMID: 32974298 PMC: 7471872. DOI: 10.3389/fbioe.2020.00922.

Co-Delivery of Teriflunomide and Methotrexate from Hydroxyapatite Nanoparticles for the Treatment of Rheumatoid Arthritis: In Vitro Characterization, Pharmacodynamic and Biochemical Investigations.

Pandey S, Kumar V, Leekha A, Rai N, Ahmad F, Verma A Pharm Res. 2018; 35(11):201.

PMID: 30187188 DOI: 10.1007/s11095-018-2478-2.

References

Ezra A, Hoffman A, Breuer E, Alferiev I, Monkkonen J, Weiss G . A peptide prodrug approach for improving bisphosphonate oral absorption. J Med Chem. 2000; 43(20):3641-52. DOI: 10.1021/jm980645y. View

Wu C, Wang C, Lu D, Hsu L, Yang K, Lin F . Calcium phosphate cement delivering zoledronate decreases bone turnover rate and restores bone architecture in ovariectomized rats. Biomed Mater. 2012; 7(3):035009. DOI: 10.1088/1748-6041/7/3/035009. View

Cenni E, Granchi D, Avnet S, Fotia C, Salerno M, Micieli D . Biocompatibility of poly(D,L-lactide-co-glycolide) nanoparticles conjugated with alendronate. Biomaterials. 2008; 29(10):1400-11. DOI: 10.1016/j.biomaterials.2007.12.022. View

Vaculikova E, Placha D, Pisarcik M, Peikertova P, Dedkova K, Devinsky F . Preparation of risedronate nanoparticles by solvent evaporation technique. Molecules. 2014; 19(11):17848-61. PMC: 6271162. DOI: 10.3390/molecules191117848. View

Shi X, Wang Y, Varshney R, Ren L, Zhang F, Wang D . In-vitro osteogenesis of synovium stem cells induced by controlled release of bisphosphate additives from microspherical mesoporous silica composite. Biomaterials. 2009; 30(23-24):3996-4005. DOI: 10.1016/j.biomaterials.2009.04.021. View

Akesson K . New approaches to pharmacological treatment of osteoporosis. Bull World Health Organ. 2004; 81(9):657-64. PMC: 2572533. View

Kyllonen L, DEste M, Alini M, Eglin D . Local drug delivery for enhancing fracture healing in osteoporotic bone. Acta Biomater. 2014; 11:412-34. DOI: 10.1016/j.actbio.2014.09.006. View

Bonnick S, Saag K, Kiel D, McClung M, Hochberg M, Burnett S . Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. J Clin Endocrinol Metab. 2006; 91(7):2631-7. DOI: 10.1210/jc.2005-2602. View

Murakami H, Takahashi N, Sasaki T, Udagawa N, Tanaka S, Nakamura I . A possible mechanism of the specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders. Bone. 1995; 17(2):137-44. DOI: 10.1016/s8756-3282(95)00150-6. View

10.

Fu Y, Fu T, Wang H, Lin C, Lee G, Wu S . Aspartic acid-based modified PLGA-PEG nanoparticles for bone targeting: in vitro and in vivo evaluation. Acta Biomater. 2014; 10(11):4583-4596. DOI: 10.1016/j.actbio.2014.07.015. View

11.

Niemi R, Vepsalainen J, Taipale H and , Jarvinen T . Bisphosphonate prodrugs: synthesis and in vitro evaluation of novel acyloxyalkyl esters of clodronic acid. J Med Chem. 1999; 42(24):5053-8. DOI: 10.1021/jm991109o. View

12.

Ogawa K, Mukai T, Inoue Y, Ono M, Saji H . Development of a novel 99mTc-chelate-conjugated bisphosphonate with high affinity for bone as a bone scintigraphic agent. J Nucl Med. 2006; 47(12):2042-7. View

13.

Saikia K, Bhattacharya T, Bhuyan S, Talukdar D, Saikia S, Jitesh P . Calcium phosphate ceramics as bone graft substitutes in filling bone tumor defects. Indian J Orthop. 2009; 42(2):169-72. PMC: 2759621. DOI: 10.4103/0019-5413.39588. View

14.

Choi S, Kim J . Design of surface-modified poly(D,L-lactide-co-glycolide) nanoparticles for targeted drug delivery to bone. J Control Release. 2007; 122(1):24-30. DOI: 10.1016/j.jconrel.2007.06.003. View

15.

Cooper C, Melton 3rd L . Epidemiology of osteoporosis. Trends Endocrinol Metab. 1992; 3(6):224-9. DOI: 10.1016/1043-2760(92)90032-v. View

16.

Nasr M, Awad G, Mansour S, Taha I, Al Shamy A, Mortada N . Different modalities of NaCl osmogen in biodegradable microspheres for bone deposition of risedronate sodium by alveolar targeting. Eur J Pharm Biopharm. 2011; 79(3):601-11. DOI: 10.1016/j.ejpb.2011.07.010. View

17.

Nordin B . International patterns of osteoporosis. Clin Orthop Relat Res. 1966; 45:17-30. View

18.

Khanna S, Pillai K, Vohora D . Bisphosphonates in phenytoin-induced bone disorder. Bone. 2010; 48(3):597-606. DOI: 10.1016/j.bone.2010.10.172. View

19.

Sahana H, Khajuria D, Razdan R, Mahapatra D, Bhat M, Suresh S . Improvement in bone properties by using risedronate adsorbed hydroxyapatite novel nanoparticle based formulation in a rat model of osteoporosis. J Biomed Nanotechnol. 2013; 9(2):193-201. DOI: 10.1166/jbn.2013.1482. View

20.

Hruby M, Konak C, Ulbrich K . Polymeric micellar pH-sensitive drug delivery system for doxorubicin. J Control Release. 2005; 103(1):137-48. DOI: 10.1016/j.jconrel.2004.11.017. View